XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.4
Revenue from Contracts with Customers (Tables)
6 Months Ended
Nov. 30, 2021
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
The following table summarizes net sales by Global Business Unit ("GBU") and geography:
Three Months Ended Nov 30, 2021
Three Months Ended Nov 30, 2020
(in thousands)United StatesInternationalTotalUnited StatesInternationalTotal
Net sales
Endovascular Therapies$36,253 $3,407 $39,660 $30,689 $3,211 $33,900 
Vascular Access20,705 4,365 25,070 20,161 3,769 23,930 
Oncology8,392 5,158 13,550 9,834 5,106 14,940 
Total$65,350 $12,930 $78,280 $60,684 $12,086 $72,770 
Six Months Ended Nov 30, 2021
Six Months Ended Nov 30, 2020
(in thousands)United StatesInternationalTotalUnited StatesInternationalTotal
Net sales
Endovascular Therapies$71,006 $6,712 $77,718 $57,669 $6,088 $63,757 
Vascular Access41,180 8,846 50,026 39,383 12,652 52,035 
Oncology17,628 9,879 27,507 17,740 9,454 27,194 
Total$129,814 $25,437 $155,251 $114,792 $28,194 $142,986 
As the Company has previously announced, the Company is focused on its ongoing transformation from a company with a broad portfolio of largely undifferentiated products to a more focused medical technology company that delivers unique and innovative health care solutions. The Company believes that this transformation will enable the Company to shift the portfolio from the mature, lower-growth markets where we have competed in the past by investing in technology and products that provide access to larger and faster growing markets. As such, we believe the growth in the near to mid-term will be driven by our high technology products including Auryon, Thrombectomy (which includes AngioVac, AlphaVac and thrombolytics) and NanoKnife. We will refer to these high technology products as our Med Tech business and we will refer to the remainder of the portfolio as our Med Device business.
The following table summarizes net sales by Med Tech and Med Device:
Three Months EndedSix Months Ended
(in thousands)Nov 30, 2021Nov 30, 2020Nov 30, 2021Nov 30, 2020
Net Sales
Med Tech$18,886 $13,849 $36,504 $24,335 
Med Device59,394 58,921 118,747 118,651 
Total$78,280 $72,770 $155,251 $142,986 
Contract Balances with Customers
The following table presents changes in the Company’s receivables, contract assets and contract liabilities with customers:
(in thousands)Nov 30, 2021
May 31, 2021
Receivables$38,205 $35,405 
Contract assets$— $— 
Contract liabilities$690 $426